Business
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced the pricing of an underwritten follow-on offering in the United States (the “Offering”) of 641,026 American Depositary Shares (“ADSs”), each representing 180 ordinary shares of Bionomics, at a public offering price of US$7.80 per ADS. The offering price of US$7.80 per ADS (A$0.0641 per ordinary share) represents a 1.63% discount to the volume weighted average price for the 15 days on which trades of the Company’s shares were recorded on ASX ending on 16 November 2022. All ADSs to be sold in the Offering will be sold by Bionomics. In addition, Bionomics has granted the underwriters an option to purchase up to an additional 96,153ADSs within 30 days from the closing date of the Offering at the public offering price, less underwriting discounts and commissions. The gross proceeds of the Offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bionomics, are expected to be approximately US$5.0 million, assuming the underwriters do not exercise their option to purchase additional ADSs, or approximately US$5.7 million, if the underwriters exercise their option to purchase additional ADSs in full. The Offering is expected to close on or about 22 November 2022 (ACDT) (21 November 2022, U.S. Eastern Time), subject to the satisfaction of customary closing conditions. Aegis Capital Corp. and Berenberg are acting as joint book-running managers for the Offering. A registration statement relating to these securities on Form F-1 (No. 333-268314) has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (“SEC”). A final prospectus supplement relating to this Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. The Offering will be made only by means of a prospectus under the U.S. Securities Act of 1933. Copies of the final prospectus relating to and describing the terms of the Offering may be obtained, when available, from (i) Aegis Ca...